A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Participants With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer

Inclusion Criteria:

- Eastern Cooperative Oncology Group (ECOG) status of 0 or 1.

- Histologically documented epithelial ovarian cancer, primary peritoneal cancer, or
fallopian tube cancer that is platinum sensitive.

- PSOC (i.e., epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube
cancer) with documented radiographic progression or relapse within 6 to 18 months of
most recent platinum-based chemotherapy.

- Female participants of childbearing potential must use effective contraception as
defined by study protocol and cannot be pregnant or breastfeeding.

NSCLC-specific Inclusion Criteria:

- Histological documentation of incurable, locally advanced, or metastatic non-squamous

- NSCLC that has progressed on prior treatment

- Not more than 2 prior regimens in the metastatic setting, including one prior
cytotoxic regimen and one prior non-cytotoxic regimen (prior treatment with adjuvant
therapy within 6 months of recurrence is considered a treatment regimen in the
metastatic setting).

- For participants with a documented epidermal growth factor receptor (EGFR) mutation or
anaplastic lymphoma kinase (ALK) rearrangement, one additional line of non-cytotoxic
prior treatment will be permitted provided the therapy is a targeted agent against the
EGFR mutation or ALK rearrangement.

- For participants with lung cancer, centrally confirmed high expression of a
sodium-dependent phosphate transporter (NaPi2b) by immunohistochemistry (IHC) is
required (i.e., IHC 2+ or 3+).

Exclusion Criteria:

- Anti-tumor therapy of any kind or major surgery within 4 weeks prior to Day 1.

- For ovarian cancer participants only, platinum-based chemotherapy within 6 months
prior to Day 1.

- For ovarian cancer participants only, platinum treatment with more than two
platinum-based chemotherapy regiments or more than four anti-cancer regimens, overall,
for the treatment of ovarian cancer.

- Palliative radiation within 2 weeks prior to Day 1.

- Toxicity (except alopecia and anorexia) from prior therapy or neuropathy of grades >
1.

- Evidence of any significant disease or condition that could affect compliance with the
protocol or interpretation of results.

- Known active infection (except fungal nail infections).

- History of liver disease or human immunodeficiency virus (HIV).

- Other malignancy within the last 5 years, except for adequately treated or controlled
carcinoma in situ of the cervix or skin cancer or primary endometrial cancer of stage

- Untreated or active central nervous system (CNS) metastases.

- Prior treatment with NaPi2b- targeted therapy.

Bevacizumab-Specific Exclusion Criteria (for Participants in Second Ovarian

Expansion Cohort Only):

- Inadequately controlled hypertension or history of hypertensive crisis or
encephalopathy.

- History of heart problems or thrombosis within 6 months prior to study start.

- History of stroke within 6 months prior to study enrollment.

- History of significant vascular disease.

- History of expectoration of blood within 1 month prior to study start or blood
clotting problems.

- Core biopsy or other minor surgical procedure within 7 days prior to study start

- Serious and non-healing wound, active ulcer, or untreated bone fracture.